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Background: Many studies had discovered that early onset severe preeclampsia (EO-PE) has worst maternal and neonatal 
outcome compared to late-onset type (LO-PE), related to its placental involvement. Severe preeclampsia was defined as 
newly onset severe hypertension developed after 20 weeks gestation in previously normal blood pressure women, with 
coexistence of proteinuria, or maternal organ or uteroplacental dysfunction. Hemeoxygenase-1 (HO-1) is an enzyme with 
multiple effect which is protective to pregnancy. 
Materials and Methods: The total study subjects were 40 pregnant women consisted of 10 EO-PE, 10 normal early onset 
pregnancy (EO-NP), 10 LO-PE, and 10 normal late onset pregnancy (LO-NP). As much as 5 cc of plasma from umbilical cord 
was taken as soon as the baby was born, and the HO-1 level was examined by enzyme-linked immunosorbent assay (ELISA). 
The primary outcome were umbilical cord HO-1 level and neonatal composite morbidity (low Apgar score, low birthweight, 
length of stay >5 day, respiratory distress syndrome, jaundice and neonatal death).
Results: The plasma level of HO-1 in EO-PE subjects were lower than EO-NP (0.96±0.37 ng/mL vs. 2.43±0.58 ng/mL, 
p<0.001). There were no significant differences in the level of HO-1 in LO-PE and LO-NP (2.18±1.07 ng/mL vs. 3.02±0.64 ng/
mL, p=0.277). Plasma level of umbilical cord HO-1 of EO-PE patients was lower compared to LO-PE (0.96±0.37 ng/mL vs. 
2.18±1.07 ng/mL, p=0.034). Neonatal outcome of EO-PE was worse than EO-NP (p=0.033), and LO-PE (p=0.003), while in 
LO-PE did not different with LO-NP (p=0.211).
Conclusion: EO-PE is associated with lower plasma umbilical cord level of HO-1 and worse neonatal outcome compared 
to LO-PE. This indicating abnormal placental blood vessel development, placental ischemia in EO-PE, lead to reduced 
uteroplacental perfusion and significantly worse neonatal outcome compared to LO-PE. 
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Introduction
 Preeclampsia is a major contributor of maternal 
and fetal morbidity and mortality worldwide.1 Recently 
preeclampsia is classified based on the onset of the disease 
into early onset preeclampsia (EO-PE) <34 week gestation 
and late onset preeclampsia (LO-PE) >34 week. These two 
type of preeclampsia were suspected to have a different 
pathophysiology, clinical manifestation and outcome.2,3 
EO-PE occurs mainly due to abnormal placentation which 
can be caused by reduced of cell protective factors (such 
as nitrite, hemeoxygenase-1 (HO-1)), or oxidative stress, 
genetic, environmental and immunological factors.2,4 
Whereas  LO-PE  is  associated  with  underlying  maternal 
disease coexisted in pregnancy, rather than abnormal 
placental development.2,3 
 Earlier study mentioned that there were two protective 
pathways in pregnancy, namely the hemeoxygenase-carbon 
monoxide/HO-CO pathway and the cysthathione-γ-lyase 
pathway.4 Deficiency in this protective pathway will lead 
to abnormal development of placental vascular system, 
eventually ended in preeclampsia. HO-1 is an enzyme that 
degrades free heme to produce a number of carbon monoxide 
(CO), iron (Fe2+), and biliverdin through cytochrome P450 
reductase (CPR).4,5 The in vivo and in vitro studies showed 
that HO-1 functions as a cytoprotector by degrading free heme 
which is highly reactive cytotoxic substance, and produces 
CO as a mediator of inhibiting inflammatory and apoptotic 
processes.4 HO-1 is expressed in the syncytiotrophoblast 
and involved in placental cell protection and relaxation of 
blood vessels during pregnancy.6 In preeclampsia, there is a 
disruption of regulation and development of placental blood 
vessels which is thought to be caused by reduced expression 
of HO-1 in the placenta. In this study we measure plasma 
HO-1 levels of umbilical cord and fetal outcome in EO-
PE, LO-PE and normal pregnancy, to determine the role of 
placental HO-1 in the pathogenesis of preeclampsia and its 
relation to the clinical outcome. 
Materials and methods
This is a comparative analytic observational study with cross 
sectional method, comparing HO-1 levels of umbilical cord 
blood of newborns and neonatal outcome in EO-PE, LO-
PE and control groups (early onset-normal preganncy (EO-
NP) and late onset-normal pregnancy (LO-NP)). This study 
was conducted in Dr. Soetomo General Hospital, Airlangga 
University Hospital and Dr. M. Soewandhi Hospital, 
Surabaya, during December 2016 - February 2017. Inclusion 
criteria were pregnant women with severe preeclampsia and 
normal pregnant women >20 weeks. Severe preeclampsia 
was diagnosed based on the International Society for The 
Study of Hypertension in Pregnancy (ISSHP) classification: 
severe hypertension (blood pressure >160/110 mmHg) 
developing after 20 weeks gestation and the coexistence 
of one of this condition (proteinuria, maternal organ 
dysfunction, or uteroplacental dysfunction). Maternal organ 
dysfunction involved: renal insufficiency (serum creatinine 
>90 umol/L), liver involvement (elevated transaminase, 
severe right upper quadrant or epigastric pain), neurological 
complication (eclampsia, altered mental status, 
blindness, stroke, hyperreflexia, etc.), and haematological 
complication.7 While the exclusion criteria were pregnant 
women who had an co-existing diseases (such as metabolic 
diseases, systemic diseases, autoimmune, gynecological 
infections and tumors), refuse to be involved in the research, 
smokers and multiple pregnancies. The sample size of each 
group was 10 patients, based on previous related study.8 
The sampling in severe preeclampsia groups was done by 
consecutive sampling method, while in control group was 
carried out using a simple randomized method. As much as 
5 cc of plasma umbilical cord was taken as soon as the baby 
is born and then HO-1 levels were examined by enzyme-
linked immunosorbent assay (ELISA) (StressXpress ELISA 
kit, StressMarq Biosciences Inc, Victoria, Canada). Babies 
were followed until they were discharged from the hospital, 
and neonatal composite morbidity was assessed. Neonatal 
composite morbidity consisted of: Apgar score <3, baby 
birthweight <2000 gram, neonatal length of stay >5 days, 
respiratory distress syndrome, jaundice and neonatal death. 
Apgar score was measured of the fetal clinical performance 
on 1st minute, based on appearance, pulse, grimace, 
activity, and respiratory.9 Respiratory distress syndrome 
was diagnosed based on clinical sign of dyspnea, grunting, 
tachypnea (respiratory rate >60x/minutes), chest indrawing, 
cyanosis, laboratory, and chest-x ray. Data was analyzed 
using Anova test, post hoc Tamhane test, Kruskal Wallis 
test, Fisher exact test, and eta association test to evaluate the 
different and the associatioan between each variable (SPSS 
23, SPSS Inc., Illinois, USA).
Results
Characteristics of Research Samples
Based on the data in Table 1, we found a significant 
differences in the age of the patients between EO-PE vs. 
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EO-NP (n=10) EO-PE (n=10) LO-NP (n=10) LO-PE (n=10)
n / Mean±SD / 
Median (range)
n / Mean±SD / 
Median (range)
n / Mean±SD / 
Median (range)
n / Mean±SD / 
Median (range)
23.1 (4.82)a 36.9 (3.04)a 24.8 (3.65) 30.8 (6.89)
<20 3 0 0 1
20-34 7 2 10 5
>35 0 8 0 4
1 (1-2)b 2 (1-4)b, c 2 (1-3) 1 (1-3)c
Primigravida 7 2 3 6
Multigravida 3 8 7 4
33 (29-33) 33 (26-33) 38 (35-40) 37 (35-39)
<34 10 10 0 0
> 34 0 0 10 10
24.7 (22.3-36.8) 24.6 (22.4-37.2) 23.9 (21.3-34.2)d 32.8 (23.8-40.1)d  
  Normal 7 4 6 1
Overweight 0 2 2 1
Obesity I 2 3 2 6
Obesity II 1 1 0 1
Obesity III 0 0 0 1
SC 1 8 4 4
Spontaneous 9 2 5 4
Extraction Vacuum 0 0 1 2
Lung Edema 0 2 0 0
Eclampsia 0 2 0 1
HELLP Syndrome 0 1 0 0
Type of Delivery2
Maternal Complication3
Variables
Age (years)1
Gravida2
UK (week)3
BMI (kg/m2)2
Table 1. General characteristics.
*Significant value p<0.05. 1One way Anova, 2Kruskal-Wallis, 3Mann-Whitney. a: comparison between a–a (p<0.001); b: 
comparison between b-b (p=0.012); c: comparison between c-c (p=0.041); d: comparison between d-d (p=0.010). 
EO-NP (p<0.001), the number of gravidity between the EO-
PE vs. EO-NP (p=0.012) and EO-PE vs. LO-PE (p=0.041). 
BMI between LO-PE vs. LO-NP was also significantly 
different (p=0.010), while other parameters did not show 
any significant different.
Plasma Umbilical Cord Hemeoxygenase-1 (HO-1) 
Plasma umbilical cord HO-1 level of EO-PE (0.96±0.37 ng/
mL) was significantly lower compared to EO-NP (2.43±0.58 
ng/mL; p<0.001), and LO-PE (2.18±1.07 ng/mL; p=0.034). 
While plasma umbilical cord HO-1 in LO-PE was not 
different with LO-NP, although tend to be lower (Figure 1, 
Table 2). The lowest HO-1 level was found in EO-PE group 
(0.55 ng/mL), and the highest was in LO-NP (3.86 ng/mL). 
Neonatal Outcome
In term of neonatal outcome, there were significant 
differences in Apgar scores (p=0.008), baby birth weight 
(p<0.001), and length of stay (p=0.001), between EO-PE 
and LO-PE (Table 3). And the length of stay of LO-PE was 
longer than LO-NP (3 vs. 2.5; p=0.038). But there were no 
significant differences in apgar score and baby birth weight 
between EO-PE vs. EO-NP, and LO-PE  vs. LO-NP. 
 The assessment of neonatal composite morbidity 
includes low Apgar score (Apgar score <3), low birth 
weight (birth weight <2000 grams), length of stay >5 days, 
complications in newborns at hospital, such as respiratory 
distress syndrome, neonatal jaundice, and neonatal death. 
Any occurrence of these variable on baby indicating 
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Figure 1. Plasma umbilical cord HO-1 level in EO-NP, EO-PE, 
LO-NP and LO-PE.
Early Onset Late Onset
Mean±SD
(ng/mL)
Mean±SD
(ng/mL)
Control 2.43±0.58 3.02±0.64 -
Severe Preeclampsia 0.96±0.37 2.18±1.07 0.034*
p -value <0.001* 0.277 -
Variable Group p -value
Hemeoksigenase -1 
(HO-1)
Table 2. Plasma levels of umbilical cord HO-1.
*Significant value p<0.05, tested with ANOVA. 
positive neonatal composite morbidity. The EO-PE had 
more neonatal composite morbidity than LO-PE and EO-
NP, indicating that the outcomes of newborns in EO-PE 
was worse compared to the LO-PE (p=0.003) and EO-NP 
(p=0.033). While the composite morbidity in LO-PE was 
not different with LO-NP (p=0.211) (Table 4). Based on 
further statistical analysis using the contingency coefficient 
test, there was a significant positive correlation of neonatal 
composite morbidity with EO-PE, with medium strength 
(p=0.010, r=0.500). It means that the occurrence of EO-PE 
increase the risk of composite neonatal morbidity.
 Based on the eta association test, a positive correlation 
was found to be very strong between plasma umbilical cord 
HO-1 level and neonatal composite morbidity (p<0.001, 
r=0.974). Low levels of plasma umbilical cord  HO-1 
correlate with worse neonatal outcome.
Discussion
This study support the hypothesis that EO-PE has a different 
pathogenesis compared to LO-PE, which is involvement of 
placenta. Plasma umbilical cord HO-1 can represent the 
level of placental HO-1, and the lower placental HO-1 is 
correlated with abnormal placental blood vessel development 
and inadequate vascularization. Our study reveal that in 
EO-PE group the plasma umbilical cord HO-1 level was 
lower than LO-PE and EO-NP. While HO-1 level in LO-
PE  was not different with LO-NP. Many studies (animal 
model and human) had already proven that deficiency of 
placental HO-1 were correlated with smaller spiral arteries, 
inadequate placental vascularization, different placental 
angiogenic profile, and significantly higher blood pressure, 
which is the main feature of placental preeclampsia.10-12 
Placental tissue of preeclampsia pregnant women has 
already proven to have a lower expression of HO-1, lower 
mRNA HO-1, and lower HO-1 protein level compared to 
normal pregnancy.6,13,14 
 Deficiency HO-1 may also shift the balance toward 
anti angiogenesis dominant, which result in endothelial cell 
damage through its relation with soluble FMS like tyrosine 
kinase-1 (sFlt-1) and soluble endoglin (sEng).15 Cudmore, 
et al., showed that induction of HO-1 in human umbilical 
endothelial vein endothelial cells (HUVECs) inhibit the 
release of sFlt-1 and sEng.16,17 Circulating sFlt-1 and sEng 
are the two main factors in the development of clinical 
syndrome of preeclampsia. Our study result indicating that 
in EO-PE (but not in LO-PE) the placenta was involved, 
reflected by the lower level of plasma HO-1. This placental 
vascular involvement in EO-PE will decrease uteroplacental 
blood flow, lead to uteroplacental insufficiency and 
correlate with poor pregnancy outcome.18 While LO-PE is 
associated with normal placental vascular development, 
normal uteroplacental perfusion, normal placental volume 
and better pregnancy outcome.2,19 Our study support this 
hypothesis with the finding that neonatal outcome and 
composite morbidity in EO-PE was worse compare to the 
LO-PE and EO-NP. Baby delivered from EO-PE woman 
had lower Apgar score, lower birth weight, and longer length 
of stay compared to LO-PE.  Since neonatal morbidity also 
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Early Onset Late Onset
Median (range) Median (range)
Control 6 (6-8) 8 (7-8) -
Severe Preclampsia 5 (3-8) 7.5 (6-8)  0.008 *
p -value 0.149 0.313 -
Control 2095 (1300-2300) 3145 (2590-3660) -
Severe Preclampsia 1900 (1000-2240) 2985 (2510-3220) <0.001 *
p -value 0.495 0.241 -
Control 7.5 (2-28) 2.5 (1-3) -
Severe Preclampsia 17 (5-30) 3 (2-7) 0.001 *
p -value 0.079 0.038 * -
Variable Group p -value
Apgar score2
Birth Weight3
(grams)
Length of stay2
(days)
Table 3. Neonatal outcome.
*Significant value p<0.05. 1One way Anova, 2Kruskal-Wallis, 3Mann-Whitney. 
Variables EO-NP EO-PE LO-NP LO-PE
Apgar score <3 0 2 0 0
Birth Weight <2000 grams 2 5 0 0
Length of Stay >5 days 5 7 0 2
Respiratory Distress Syndrome 1 3 0 0
Neonatal Jaundice 2 7 0 3
Neonatal Death 1 3 0 0
Neonatal Composite Morbidity 5 10 0 3
Table 4. Composite neonatal morbidity.
closely related to gestational age at the time of delivery, 
more severe form of EO-PE often necessitate iatrogenic 
preterm delivery, which result in prematurity. Prematurity 
will directly increase neonatal morbidity (respiratory 
distress syndrome, neonatal jaundice) and mortality. Our 
finding is in line with many recent studies which stated 
that neonatal outcome in EO-PE was worse compared to 
LO-PE.19-21 And also the neonatal outcome in LO-PE was 
not different with the LO-NP, indicating relatively normal 
placental development and uteroplacental perfusion in this 
type of preeclampsia.  
 This study also reveal a strong correlation between 
plasma umbilical cord HO-1 level with neonatal composite 
morbidity. It means that low umbilical cord HO-1 level is 
correlated with poor neonatal outcome. Many studies had 
proven that deficiency HO-1 in placenta and circulation 
was correlated with poor pregnancy outcome, such as 
miscarriage, intra uterine growth restriction, intra uterine 
fetal death, and preterm labour.22-27 This might be explained 
by an unopposed free fetal heme on deficient HO-1 placenta 
that stimulates cell damage, subsequently lead to abnormal 
placentation.27 But as far as we know, this was the first 
study to evaluate the relationship between placental HO-1 
and neonatal outcome. The strong relationship between low 
level of placental plasma HO-1 and neonatal composite 
morbidity (especially in EO-PE) could provide clue about 
the role of placental HO-1 deficiency in the development of 
more severe type of  preeclampsia with abnormal placental 
development and poor neonatal outcome. Defficiency of 
placental HO-1 was correlated with increased level of 
sFlt-1 and sEng, which associated with clinical severity 
of preeclampsia.4 Study on animal model showed that 
induction of HO-1 inhibit sFlt-1 and sEng level, increased 
VEGF level, improved endothelial fuction, and decreased 
blood pressure.16,17,28  
 Our study result indicate that in the future, HO-1 
inducer (statin) may be used to protect the normal placental 
vascular development in pregnancy, prevent placental 
insufficiency syndrome such as preeclampsia (especially the 
early type), and improve the neonatal outcome. 
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Conclusion
This study reveal that defficiency placental HO-1 is 
correlated with poor neonatal outcome (especially in EO-
PE) via abnormal placental vascular development. HO-1 
inducer (statin) should be consider as a new approach in the 
future to protect vascular placental insufficiency, prevent 
subsequent preeclampsia syndrome, and improve neonatal 
outcome.
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